Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd., a foreign private issuer, covers the month of December 2015. The report was filed on December 22, 2015, and primarily serves to disclose a significant corporate governance change rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a personnel appointment and does not contain financial statements or operational metrics.
Material Changes
The material change disclosed in this filing is the appointment of Eyal Leibovitz as the new Chief Financial Officer (CFO), as detailed in the attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The scope is limited to the executive appointment.
Key Facts for Investor Verification
- Evogene Ltd. has appointed Eyal Leibovitz as its new Chief Financial Officer.
- The filing date is December 22, 2015.
- No financial data or operational results are included in this specific report.
- Investors should review the attached press release (Exhibit 99.1) for details on the new CFO's background and the transition plan.